tiprankstipranks

Black Diamond price target lowered to $11 from $12 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Black Diamond Therapeutics to $11 from $12 and keeps a Buy rating on the shares following the Q1 report. The firm is cautious in ascribing value to BDTX-1535 in brain cancer.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue